COVID-19 associated ketosis and diabetic ketoacidosis: A rapid review

Diabetes Obes Metab. 2023 Jul;25(7):1785-1793. doi: 10.1111/dom.15036. Epub 2023 Mar 17.

Abstract

SARS-CoV-2 infection could disrupt the endocrine system directly or indirectly, which could result in endocrine dysfunction and glycaemic dysregulation, triggering transient or persistent diabetes mellitus. The literature on the complex relationship between COVID-19 and endocrine dysfunctions is still evolving and remains incompletely understood. Thus, we conducted a review on all literature to date involving COVID-19 associated ketosis or diabetic ketoacidosis (DKA). In total, 27 publications were included and analysed quantitatively and qualitatively. Studies included patients with DKA with existing or new onset diabetes. While the number of case and cohort studies was limited, DKA in the setting of COVID-19 seemed to increase risk of death, particularly in patients with new onset diabetes. Future studies with more specific variables and larger sample sizes are needed to draw better conclusions.

Keywords: diabetes complications; endocrine therapy; real-world evidence; systematic review; type 1 diabetes; type 2 diabetes.

Publication types

  • Review

MeSH terms

  • COVID-19* / complications
  • Cohort Studies
  • Diabetes Mellitus, Type 1* / complications
  • Diabetic Ketoacidosis* / complications
  • Diabetic Ketoacidosis* / therapy
  • Humans
  • Ketosis* / complications
  • SARS-CoV-2